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Background: Microbial transformation of steroids has been extensively used for the synthesis of steroidal drugs,
that often yield novel analogues, not easy to obtain by chemical synthesis. We report here fungal transformation of
a synthetic steroidal drug, exemestane, used for the treatment of breast cancer and function through inhibition of
aromatase enzyme.
Results: Microbial transformation of anti-cancer steroid, exemestane (1), was investigated by using two filamentous
fungi. Incubation of 1 with fungi Macrophomina phaseolina, and Fusarium lini afforded three new, 11α-hydroxy-6-
methylene-androsta-1, 4-diene-3,17-dione (2), 16β, 17β-dihydroxy-6-methylene-androsta-1, 4-diene-3-one (3), and
17β-hydroxy-6-methylene-androsta-1, 4-diene-3, 16-dione (4), and one known metabolites, 17β-hydroxy-6-
methylene-androsta-1, 4-diene-3-one (5). Their structures were deduced spectroscopically. Compared to 1 (steroidal
aromatase inactivator), the transformed metabolites were also evaluated for cytotoxic activity by using a cell
viability assay against cancer cell lines (HeLa and PC3). Metabolite 2 was found to be moderately active against
both the cell lines.
Conclusions: Biotransformation of exemestane (1) provides an efficient method for the synthesis of new analogues
of 1. The metabolites were obtained as a result of reduction of double bond and hydroxylation. The transformed
product 2 exhibited a moderate activity against cancer cell lines (HeLa and PC3). These transformed products can
be studied for their potential as drug candidates.
Keywords: Steroid, Exemestane, Anti-cancer activity, Cancer cell lines (HeLa, PC3), Fusarium lini, Macrophomina
phaseolina, Microbial transformationBackground
Microbial transformation of steroids has been exten-
sively employed for the synthesis of steroidal drugs, both
at laboratory and industrial levels [1-7]. In modern drug
discovery process, generation of libraries of bioactive
compounds with diverse structures plays an important
role [8].
Exemstane (trade name aromasin) is a steroidal irre-
versible aromatase inhibitor, used for the treatment of
breast cancer. Breast cancers have estrogen receptors* Correspondence: eliasbay1@yahoo.com; iqbal.choudhary@iccs.edu
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distribution, and reproduction in any medium(ER-positive) and their growth depends on aromatase
activity. Therefore, inhibition of aromatase enzyme
reduces the estrogen levels and thus slows the growth of
breast cancer [9-12].
Interestingly exemestane not only increases the tes-
tosterone level and lowers estrogen, but it also increases
the levels of insulin-like growth factor (IGF) [10]. The
large reduction in estrogen levels combined with a rise
in IGF, makes exemestane an effective breast cancer
medication [13-15]. Based on the importance of
exemestane in the treatment of breast cancer, a number
of exemestane derivatives were previously synthesized
involving modification of C-6 methylene and reductionntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,






























Figure 1 Biotransformation of exemestane (1) with Fusarium lini yielded metabolite 2.
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http://journal.chemistrycentral.com/content/7/1/57of C-17 keto group, and evaluated for their aromatase
inhibitory potential [16-19].
During current study, we synthesized new ana-
logues of 1 by biotransformation techniques. Screening















Figure 2 Biotransformation of exemestane (1) with Macrophomina phFusarium lini were able to efficiently transform 1 into sev-
eral metabolites. Subsequent large scale fermentations
produced three new metabolites 2−4 along with a known
metabolite 5. The structures of metabolites were unam-























aseolina yielded metabolites 3-5.
Table 1 1H-NMR data of compounds 1–5 in ppm, J in Hz
COMPOUNDS
Carbon 1a 2a 3b 4b 5b
1 7.21 d (10.0) 7.21 d (10.5) 7.31 d (10.2) 7.34 d (10.5) 7.31 d (10.2)
2 6.14 dd (10.5, 2.0) 6.12 dd (10.5, 2.0) 6.21 dd (10.2, 1.8) 6.42, dd (10.5, 2.0) 6.22 dd (10.2, 1.8)
3 - - - - -
4 5.99, d (2.0) 6.00 d (2.0) 6.08 d (1.8) 6.11 d (2.0) 6.09 d (1.8)
5 - - - - -
6 - - - - -
7 2.69, 1.97 m 2.13, 1.28 m 2.56 d (9.0), 1.87 m 2.57, 1.96 m 2.66, 1.82 m
8 2.03 m 1.98 m 1.86 m 1.98 m 1.83 m
9 1.34 m 1.62 m 1.35 m 1.48 m 1.05 m
10 - - - - -
11 1.92, 1.76 m 4.30 m 1.91, 1.31 m, 1.93, 1.84 m 1.75, 1.83 m
12 1.78, 1.28 m 2.13, 1.28 m 1.90, 1.16 m 2.01, 1.45 m 1.13, 1.92 m
13 - - - - -
14 1.43 m 1.37 m 0.93 m 1.63 m 1.27 m
15 1.99, 1.67 m 1.93, 1.80 m 2.20, 1.30 m 2.29, 1.95 m 1.65, 1.38 m
16 2.41, 1.95 m 2.66, 1.95 m 4.07 m - 2.00, 1.51 m
17 - - 3.30 d (7.5) 3.77 s 3.55 t (8.7)
18 0.92 s 0.99 s 0.99 s 0.81 s 0.81 s
19 1.19 s 1.18 s 1.18 s 1.21 s 1.17 s
20 5.03, 5.01 s 5.04, 5.02 s 5.02 t (1.9) 5.06, 5.04 s 4.99, 5.01 s
a 500 MHz (CD3)2CO.
b 300 MHz CD3OD.
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exemestane showed a moderate anti-cancer effect against
PC3 and/or Hela cancer cell lines. This successful attempt
to synthesize new derivatives of an anti-cancer steroid may
lead to the discovery of new cancer therapeutic agents.
Results and discussion
Four microbial metabolites were generated by the se-
lected fungal strains, i.e. Macrophomina phaseolina and
Fusarium lini (Figures 1 and 2). M. phaseolina is previ-
ously reported to catalyze the introduction of double bond
between C-1 and C-2, hydroxyl groups at C-6, C-15, C-16
and C-17, and carbonyl group at C-17 of the steroidal
skeleton [1,20]. F. lini is also reported to catalyze the oxi-
dation at C-1, C-2, C-6, and C-11 of steroidal skeleton
[21]. The chemical structures of the metabolites 2−4 are
reported here for the first time along with their NMR data
(Tables 1 and 2).
The anti-cancer effect of exemestane (1) [2] and its
synthetic analogues on HeLa and PC3 were determined
by using MTT assay. Results obtained from these assays
are presented in Table 3.
The molecular formula C20H24O3 [M
+, m/z 312] of
metabolite 2 was deduced from the HREI-MS (M+ m/z312.1705), suggested the addition of an oxygen in sub-
strate 1. The 1H-NMR spectral analysis of 2 (Table 1)
displayed a downfield methine signal, as compared to
the starting material exemestane (1), resonating at
δ 4.30 (m, W1/2 = 15.6 Hz), while its respective carbon
signal was at δ 71.5 in 13C-NMR spectrum (Table 2).
The HMBC spectrum (Figure 3) displayed long-range
couplings of the hydroxyl-bearing methine proton (δ 4.30)
with C-9 (δ 48.6), C-10 (δ 44.3), and C-13 (δ 48.1),
which suggested the position of the hydroxyl-bearing
methine at C-11. H-11 also showed COSY cross peaks
with H-9 (δ 1.62) and H2-12 (δ 1.28, 2.13). The stereo-
chemical assignments were based on NOESY interactions
(Figure 3) between H-11 (δ 4.30), H-8 (δ 1.98), and Me-19
(δ 1.18). H-11 was thus deduced as β-oriented. Metabolite
2 was finally identified as 11α-hydroxy-6-methylene-
androsta-1,4-diene-3,17-dione.
Molecular composition of metabolite 3 was deduced to
be C20H26O3 from the HREI-MS analysis (M
+ = m/z
314.1933, calcd 314.1882). The 1H-NMR spectra μm
(Table 1) of metabolite 3 showed two hydroxyl-bearing
methine proton peaks at δ 3.30 (d, J17,16 = 7.5 Hz, H-17)
and 4.07 (m, W1/2 = 20.0 Hz). The
13C-NMR spectrum of
3 lacks signal for C-17 carbonyl, whereas new methine
Table 2 13C-NMR data of compounds 1–5 in ppm
COMPOUNDS
Carbon 1a 2b 3c 4d 5d
1 155.0 154.9 158.1 157.6 158.2
2 128.0 128.0 127.8 127.9 127.7
3 185.8 185.8 188.7 188.6 188.7
4 122.9 122.9 122.7 122.8 122.7
5 167.9 167.9 171.6 171.2 171.7
6 147.1 147.0 147.7 147.3 147.8
7 39.87 32.1 41.4 41.2 41.3
8 36.0 39.6 36.6 35.9 37.2
9 50.9 48.6 51.9 51.4 51.7
10 44.3 44.3 45.6 45.5 45.6
11 22.63 71.5 23.0 23.2 23.6
12 32.0 32.0 38.1 36.6 37.5
13 48.1 48.1 43.7 43.5 44.2
14 51.3 50.8 48.2 45.4 51.8
15 22.3 22.3 35.9 36.6 24.3
16 35.8 39.7 70.6 217.7 30.5
17 218.8 218.0 81.7 86.8 82.1
18 13.9 14.5 12.5 11.9 11.6
19 20.1 20.1 20.1 20.1 20.1
20 112.2 112.2 112.6 112.9 112.4
a 125 MHz (CD3)2CO.
b 150 MHz (CD3)2CO.
c 125 MHz CD3OD.
d 75 MHz CD3OD.
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into C-17 OH. The proton geminal to the –OH group
(δ 4.07) was correlated with C-13 (δ 43.7), C-14 (δ 48.2)
and C-17 (δ 81.7) in the HMBC spectrum. The methine
C-17 (δ 81.7) showed HMBC correlations with H-14
(δ 0.93, m) and H-18 (δ 0.99, s). Based on the above
observations, the hydroxyl-bearing methine carbon was
identified as C-16. The H-16 (δ 4.07) showed NOESY cross
peaks with H-14 (δ 0.93), but no interaction with H-18
(δ 0.99) (Figure 4). Therefore the C-16 proton was assigned
to be α-oriented. The metabolite 3 was thus identified as
16β, 17β-dihydroxy-6-methylene-androsta-1, 4-diene-3-one.Table 3 In vitro cytotoxicity of compounds 1–5







4 37.20 ± 0.88 >50
5 >50 >50
Doxorubicin 3.10 ± 0.20 0.91 ± 0.12Molecular formula C20H24O3 (M
+ m/z 312.1725, calcd
312.1720) was deduced from the HREI-MS of metabolite
4. A distinct downfield methine proton signal appeared at
δ 3.77 (br. s, W1/2 = 9.3 Hz) in the
1H-NMR spectrum of
4. The 13C-NMR spectrum showed a saturated ketone
carbon signal at δ 217.7. The rest of the spectrum was
distinctly similar to metabolite 2. The deshielded methine
proton was HMBC correlated with this ketonic carbon,
while its corresponding methine carbon at δ 86.8 showed
the HMBC correlations with H2-15 (δ 1.95, 2.29), and
CH3-18 (δ 0.81). These interactions, along with appear-
ance of a downfield proton (δ 3.77), indicated that the
ketone at C-17 has been reduced into an –OH. Geminal
H-17 (δ 3.77) showed NOESY correlations with H-14
(δ 1.63), indicating it to be axially (α-) oriented. The satu-
rated ketone carbon (δ 217.7) was place at C-16, based on
the above mentioned HMBC correlations (Figure 5). The
structure of metabolite 4 was finally identified as 17β-
hydroxy-6-methylene-androsta-1, 4-diene-3, 16-dione.
Metabolite 5 has a molecular composition C20H26O2
(HREI-MS, M+ m/z 298.1730, calcd 298.1733). Based on
1H- and 13C-NMR spectral data (Tables 1 and 2), com-
pound 5 was identified as 17β-hydroxy-6-methylene-
androsta-1, 4-diene-3-one. It has previously been reported
as an in-vitro cytochrome P450-mediated transformed
product of exemestane [22].
The cytotoxic effect of the compounds 1-5 against
two tumor cell lines, PC-3 (prostate cancer cell) and
Hela (cervical cancer cell), was evaluated (Table 3)
using the MTT assay. Compound 2 showed a moder-
ate cytotoxicity against both the cancer cell line with
IC50 = 16.83 ± 0.96 and 24.87 ± 0.72 μM, respectively, as
compared to the standard drug, doxorubicin. Compound
4 exhibited a moderate activity against HeLa cell line.
Conclusion
In conclusion, the biotransformation of exemestane (1)
with F. lini and M. phaseolina were investigated for the
first time which provided an efficient route towards the
synthesis of several new metabolites 2–5. Metabolite 2
was found to be moderately active against both cancer cell
lines (HeLa and PC3). The work presented here can be
helpful for the study of in vivo metabolism of exemestane
(1), as well as for the discovery of new anticancer drugs
Experimental
Substrate and chemicals
Exemestane (1) was purchased from local market as drug
(Pfizer Canada Inc., Brand name Aromasin), extracted and
further purified by flash chromatography. Thin layer chro-
matography (TLC) was carried out on silica gel precoated
plates (PF254; Merck). Column chromatography (CC)
was performed by using silica gel (E. Merck, Germany).




















































Figure 3 Important HMBC (a) and NOESY (b) correlations in metabolite 2.
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were recorded in (CD3)2CO and CD3OD on Bruker
Avance spectrometers. The chemical shifts (δ values) are
presented in ppm and the coupling constants (J) are in
Hz. For 1D- and 2D-NMR experiments, standard Bruker
pulse sequences were used. UV Spectra (in nm) were
recorded in methanol with a Hitachi U-3200 spectropho-
tometer. Infrared (IR) spectra (in cm-1) were recorded
with an FT-IR-8900 spectrophotometer. JEOL (Japan)
JMS-600H mass spectrometer was used for recording of
EI-MS and high-resolution mass spectra (HREI-MS) in
m/z (rel. %).
The anticancer activity of compounds 2-5 was evalu-
ated in 96-well flat-bottomed micro-titer plates [Iwaki,
Japan] by using the standard dye MTT (3-[4, 5-
dimethylthiazole-2-yl]-2, 5-diphenyl-tetrazolium bromide)
[Sigma-Aldrich Chemicals, St. Louis, USA] through
colorimetric analysis. For this purpose, the cells were
cultured in Minimum Essential Medium (MEM),
supplemented with 10% Fetal Calf Serum (FCS), 1 mmol/
l sodium pyruvate, 1% (v/v) antibiotic / antimycotic and
passaged weekly, using 0.25% trypsin / EDTA [Sigma-




























Figure 4 Important HMBC (a) and NOESY (b) correlations in metaboliflasks T-75 [Iwaki, Japan]. Absorbance was taken at 540
nm wavelength by using microplate reader (Spectra
Max plus, Molecular Devices, USA) using software
SoftMax Pro 340 [Molecular Devices, CA, USA]. Di-
methyl sulfoxide (DMSO) and doxorubicin (standard
inhibitor) were purchased from Sigma-Aldrich Chemicals,
[St. Louis, USA].Microorganisms and culture medium
The fungi were purchased from the Northern Regional
Research Laboratories (NRRL), or obtained as gift from
the Karachi University Culture Collection (KUCC).
Fusarium lini (NRRL 2204), and Macrophomina
phaseolina (KUCC 730) were grown in a culture
medium prepared by mixing glucose (40.0 g), glycerol
(40.0 mL), peptone (20.0 g), yeast extract (20.0 g),
KH2PO4 (20.0 g), and NaCl (20.0 g) in distilled H2O (4.0 L).Cell lines
PC3 (prostate cancer) and HeLa (cervical cancer) cell
lines were purchased from the American Type Culture














































































Figure 5 Important HMBC (a) and NOESY (b) correlations in metabolite 4.
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4 Liters fungal media was prepared and distributed into 40
conical flasks (100 mL in each flask). All flasks were then
autoclaved at 121°C. The fungal cultures were then inocu-
lated into each flask containing media and incubated at
room temperature on shaker for three days. Compound 1
was dissolved in 40 mL methanol and distributed equally
to all 40 flasks. All experimental flasks were then kept for
fermentation. Two control experiments, i.e. media + com-
pound 1 and media + fungus were also conducted. The
transformation was then checked on TLC. After the detec-
tion of transformation on TLC, fungal culture from all 40
flasks was filtered and extracted with CH2Cl2 (12 L) by
using liquid-liquid chromatography. The dichloromethane
layer was evaporated in vaccue. The obtained gum was
analyzed by thin-layer chromatography.
Fermentation and Purification of Exemestane (1) with
Fusarium lini
Exemestane (1; 1.0 g) was dissolved in 40 mL methanol,
and incubated with culture of F. Lini. The obtained gum
(2.3 g) was fractionated (ARC 1-3) by using silica gel
column chromatography. The mobile phase was com-
posed of petroleum ether and acetone with a gradient of
10%. Fraction ARC-2 yielded metabolite 2 (4 mg, pet.
ether: acetone = 8:2) after elution through silica
gel column.
11α-Hydroxy-6-methylene-androsta-1,4-diene-3,17-
dione (2) Amorphous material; [α]25D: +81.4 (c = 0.096,
MeOH); IR (KBr): νmax 3408, 1657 cm
-1; UV
(MeOH): λmax nm (log ε) 247 (3.78);
1H- and 13C-
NMR: see Tables 1 and 2 (Additional file 1).
Fermentation and Purification of Exemestane (1)
with Macrophomina phaseolina Incubation of 1 (1.0 g /
40 mL methanol) with 3 days old culture of M. phaseolina
in 40 flasks for 12 days produced the metabolites 3
(10 mg), 4 (5 mg) and 5 (6 mg).16β, 17β-Dihydroxy-6-methylene-androsta-1,4-diene-
3-one (3) Amorphous material; [α]25D: +181.6 (c =
0.032, MeOH); IR (KBr): νmax 3388, 1658 cm
-1; UV
(MeOH): λmax nm (log ε) 249 (4.03);
1H- and 13C-
NMR: see Tables 1, and 2 (Additional file 2).
17β-Hydroxy-6-methylene-androsta-1,4-diene-3,16-
dione (4) Amorphous material; [α]25D: -56.0 (c = 0.043,
MeOH); IR (KBr): νmax 3411, 1749, 1658 cm
-1; UV
(MeOH): λmax nm (log ε) 247 (4.04);
1H- and 13C-NMR:
see Tables 1 and 2 (Additional file 3).
17β-Hydroxy-6-methylene-androsta-1,4-diene-3-one
(5) Amorphous material; [α]25D: +174.5 (c = 0.046,
MeOH); IR (KBr): νmax 3421, 1657, cm
-1; UV (MeOH):
λmax nm (log ε) 248 (4.24);
1H- and 13C-NMR: see
Tables 1 and 2 (Additional file 4).
Cell Viability Assay
The cytotoxicity of metabolites 1-5 were determined by
using MTT-based colorimetric assay in 96-well plate [23].
Both cell lines (PC-3 and HeLa) were cultured in DMEM
and MEM media, respectively, in 25 cm3 tissue culture
flasks. The media were supplemented with FBS (5%),
pencillin (100 IU/mL) and streptomycin (100 mg/mL).
The flasks were then incubated at 37°C in an incubator
containing 5% CO2. The flask (80% confluence) was
processed for MTT-based cytotoxicity assay. The percent
viability of the cells was monitored by trypan blue dye.
The cells with clear cytoplasm were considered viable. For
the assay, the cells (1 × 105) were loaded onto 96-well tis-
sue culture treated plate. The plate was incubated for 24
hours at 37°C. After incubation, the cells were treated with
different concentrations (1.56-50 μM dissolved in DMSO)
of compounds 1-5 and kept in an incubator for 48 hours
at 37°C. At the end of the incubation, the MTT dye (50
μL, 2 mg/mL) was added to each well and the plate was
incubated for 4 hours at 37°C in an incubator. Following
incubation, the insoluble formazan crystals were dissolved
by adding DMSO (100 μL).
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toxic effects of the compounds.
% Inhibition ¼ 100 ½ðAbsorbance of test compound
Absorbance of blankÞ=
ðAbsorbance of control
Absorbance of blankÞ  100
Additional files
Additional file 1: Spectroscopic data of metabolite 2. Include spectra
of EI-MS, UV, IR, 1H-NMR, 13C-NMR (BB, DEPT-135°, DEPT-90°), HMQC,
HMBC, COSY-45°, NOESY experiments.
Additional file 2: Spectroscopic data of metabolite 3. Include spectra
of EI-MS, UV, IR, 1H-NMR, 13C-NMR (BB, DEPT-135°, DEPT-90°), HSQC,
HMBC, COSY-45°, NOESY experiments.
Additional file 3: Spectroscopic data of metabolite 4. Include spectra
of EI-MS, UV, IR, 1H-NMR, 13C-NMR (BB, DEPT-135°, DEPT-90°), HMQC,
HMBC, COSY-45°, NOESY, experiments.
Additional file 4: Spectroscopic data of metabolite 5. Include spectra
of EI-MS, UV, IR, 1H-NMR, 13C-NMR (BB, DEPT-135°, DEPT-90°), HSQC,
HMBC, COSY-45°, NOESY experiments.
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